parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in retinal pigment epithelial cells	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 16267

EFR3B in dopamine neurons, braak-0.33 (p 0.385) → -0.29 (p 0.457)receipt 16275
EFR3B in astrocytes, braak+0.19 (p 0.618) → +0.22 (p 0.563)receipt 16274

receipt 16275: EFR3B in dopamine neurons, braak

power: full sample -0.32 (p 0.194, n 18), 95% CI -0.69 to +0.17. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.32 (p 0.194, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.33 (p 0.176, n 18). could be the mix.
skeptic: leave-one-out range -0.42 to -0.22, sign flips 0; without severely affected donors -0.32 (p 0.194, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for EFR3B in dopamine neurons.

case closed: nothing better to follow up.

receipt 16274: EFR3B in astrocytes, braak

power: full sample +0.11 (p 0.664, n 18), 95% CI -0.38 to +0.55. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.11 (p 0.664, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.06 (p 0.820, n 18). could be the mix.
skeptic: leave-one-out range +0.02 to +0.24, sign flips 0; without severely affected donors +0.11 (p 0.664, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for EFR3B in astrocytes.

case closed: nothing better to follow up.

loading the receipts